https://orcid.org/0000-0002-8460-9838
References
- https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/125514Orig1s000ltr.pdf
- Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a Meta-Analysis. Oncologist. 2017;22(4):470.
- Xu C, Chen Y-P, Du X-J, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. Bmj. 2018;363:k4226.
- Konala VM, Adapa S, Aronow WS. Immunotherapy in bladder cancer. Am J Ther. 2019 Feb;Publish Ahead of Print. DOI:10.1097/MJT.0000000000000934.
- Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016;29(6):806–812.
- Ghosh PS, Swift D, Engel AG. Teaching neuroimages: hydroxychloroquine-induced vacuolar myopathy. Neurology. 2013;80(23):e248–9.
- Pasnoor M, Barohn RJ, Dimachkie MM. Toxic myopathies. Neurol Clin. 2014;32(3):647–670.
- De Maleissye M-F, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med. 2016;375(3):296–297.
- Lawson VH, Arnold WD. Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment. Neuropsychiatr Dis Treat. 2014;10:567.
- Johnson DB, Manouchehri A, Haugh AM, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7(1):134. .
- Schneiderbauer R, Schneiderbauer M, Wick W, et al. antibody-induced Guillain-Barre syndrome in a patient with metastatic melanoma. Acta Derm Venereol. 2017;97(3):395–396.
- Spain L, Tippu Z, Larkin JM, et al. How we treat neurological toxicity from immune checkpoint inhibitors. ESMO Open. 2020;4(Suppl 4):e000540.
- Kennedy LC, Bhatia S, Thompson JA, et al. Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. J National Compr Cancer Network. 2019;17(6):750–757.